NCT05372640View on ClinicalTrials.gov

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Malignant Solid NeoplasmUnresectable Breast CarcinomaUnresectable Malignant Solid Neoplasm
Interventions
DRUG

Abemaciclib

Given PO

DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Diagnostic Imaging Testing

Undergo imaging evaluation

Trial Locations (7)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

77030

RECRUITING

M D Anderson Cancer Center, Houston

90020

RECRUITING

Keck Medicine of USC Koreatown, Los Angeles

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

RECRUITING

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH